As Alexion Pharmaceuticals (ALXN) Share Price Declined, Teacher Retirement System Of Texas Has Trimmed Its Position by $1.33 Million; As Monsanto Co New (MON) Share Value Rose, Holder Talara Capital Management Has Lowered Its Position by $687,880

April 23, 2018 - By Adrian Mccoy

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Logo

David Zusman decreased its stake in Monsanto Co New (MON) by 8.71% based on its latest 2017Q4 regulatory filing with the SEC. Talara Capital Management Llc sold 5,930 shares as the company’s stock rose 1.12% while stock markets declined. The hedge fund run by David Zusman held 62,181 shares of the agricultural chemicals company at the end of 2017Q4, valued at $7.26 million, down from 68,111 at the end of the previous reported quarter. Talara Capital Management Llc who had been investing in Monsanto Co New for a number of months, seems to be less bullish one the $55.16B market cap company. The stock increased 0.32% or $0.4 during the last trading session, reaching $125. About 3.71M shares traded. Monsanto Company (NYSE:MON) has risen 3.06% since April 23, 2017 and is uptrending. It has underperformed by 8.49% the S&P500.

Teacher Retirement System Of Texas decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 10.61% based on its latest 2017Q4 regulatory filing with the SEC. Teacher Retirement System Of Texas sold 11,218 shares as the company’s stock declined 8.80% with the market. The institutional investor held 94,524 shares of the health care company at the end of 2017Q4, valued at $11.30M, down from 105,742 at the end of the previous reported quarter. Teacher Retirement System Of Texas who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $23.97 billion market cap company. The stock decreased 3.54% or $3.96 during the last trading session, reaching $107.78. About 5.46M shares traded or 150.17% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since April 23, 2017 and is downtrending. It has underperformed by 20.39% the S&P500.

Since January 9, 2018, it had 0 insider purchases, and 1 sale for $966,720 activity.

Investors sentiment decreased to 0.81 in 2017 Q4. Its down 0.03, from 0.84 in 2017Q3. It dived, as 69 investors sold MON shares while 328 reduced holdings. 75 funds opened positions while 246 raised stakes. 317.44 million shares or 1.24% less from 321.42 million shares in 2017Q3 were reported. Highlander Limited Co reported 200 shares. Cullen Frost Bankers Incorporated accumulated 9,032 shares or 0.03% of the stock. Ipswich Management Company Incorporated reported 1,739 shares stake. Sol Mngmt owns 2,500 shares or 0.08% of their US portfolio. Moreover, Clenar Muke Llc has 0.28% invested in Monsanto Company (NYSE:MON). Winslow Evans And Crocker Incorporated holds 0.01% or 188 shares. Tci Wealth Advsr reported 820 shares or 0.04% of all its holdings. Castleark Ltd Liability Co reported 6,120 shares. Lpl Fincl Ltd Liability Corporation holds 0.02% in Monsanto Company (NYSE:MON) or 63,901 shares. Whittier Tru Company Of Nevada has invested 0.04% in Monsanto Company (NYSE:MON). 32,656 are owned by Hendley Inc. S&Co Inc, a Massachusetts-based fund reported 1,800 shares. Piedmont Investment Advsrs Ltd Liability Corporation owns 94,323 shares. Moreover, Brown Advisory Inc has 0.06% invested in Monsanto Company (NYSE:MON). Old Mutual Customised Solutions (Proprietary), a South Africa-based fund reported 7,692 shares.

Among 23 analysts covering Monsanto Company (NYSE:MON), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Monsanto Company had 63 analyst reports since August 25, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Hold” rating and $128.0 target in Monday, November 13 report. The company was downgraded on Monday, April 16 by Argus Research. On Wednesday, July 12 the stock rating was downgraded by Jefferies to “Hold”. The stock of Monsanto Company (NYSE:MON) earned “Buy” rating by Stifel Nicolaus on Friday, October 9. Jefferies maintained Monsanto Company (NYSE:MON) on Friday, September 15 with “Hold” rating. Barclays Capital maintained Monsanto Company (NYSE:MON) on Thursday, June 29 with “Hold” rating. The rating was maintained by Barclays Capital on Thursday, October 6 with “Equal-Weight”. The stock has “Market Perform” rating by Wells Fargo on Tuesday, October 10. The firm has “Overweight” rating given on Tuesday, December 1 by Atlantic Securities. On Friday, September 11 the stock rating was initiated by Bernstein with “Underperform”.

Analysts await Monsanto Company (NYSE:MON) to report earnings on June, 27. They expect $2.19 earnings per share, up 13.47% or $0.26 from last year’s $1.93 per share. MON’s profit will be $966.42 million for 14.27 P/E if the $2.19 EPS becomes a reality. After $3.22 actual earnings per share reported by Monsanto Company for the previous quarter, Wall Street now forecasts -31.99% negative EPS growth.

Talara Capital Management Llc, which manages about $249.36 million and $188.65 million US Long portfolio, upped its stake in Waste Connections Inc by 55,272 shares to 146,381 shares, valued at $10.38M in 2017Q4, according to the filing.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 25 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Alexion Pharmaceuticals Inc. had 105 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by Credit Suisse on Monday, July 11. The firm has “Buy” rating by Goldman Sachs given on Friday, October 28. On Monday, October 23 the stock rating was maintained by SunTrust with “Buy”. Robert W. Baird maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Tuesday, September 12. Robert W. Baird has “Hold” rating and $145.0 target. The stock has “Buy” rating by Oppenheimer on Thursday, July 27. The firm has “Hold” rating given on Wednesday, June 7 by Jefferies. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Hold” rating by Jefferies on Thursday, August 31. Jefferies maintained the stock with “Hold” rating in Friday, September 23 report. The firm has “Buy” rating by Deutsche Bank given on Thursday, November 3. Credit Suisse reinitiated it with “Outperform” rating and $147 target in Thursday, January 18 report.

Since January 2, 2018, it had 0 insider buys, and 12 selling transactions for $4.62 million activity. On Monday, February 5 O’Neill Julie sold $248,474 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 2,119 shares. Shares for $76,805 were sold by Wagner Heidi L. $1.54 million worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by HANTSON LUDWIG. Shares for $147,865 were sold by Moriarty John B. $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Clancy Paul J. Franchini Indrani Lall sold $169,696 worth of stock or 1,459 shares.

Teacher Retirement System Of Texas, which manages about $14.97 billion US Long portfolio, upped its stake in Caci Intl Inc (NYSE:CACI) by 6,382 shares to 8,395 shares, valued at $1.11 million in 2017Q4, according to the filing. It also increased its holding in Cree Inc (NASDAQ:CREE) by 25,045 shares in the quarter, for a total of 33,080 shares, and has risen its stake in Rollins Inc (NYSE:ROL).

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on April, 26 before the open. They expect $1.28 earnings per share, up 6.67% or $0.08 from last year’s $1.2 per share. ALXN’s profit will be $284.62M for 21.05 P/E if the $1.28 EPS becomes a reality. After $1.28 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment decreased to 1.03 in 2017 Q4. Its down 0.14, from 1.17 in 2017Q3. It is negative, as 65 investors sold ALXN shares while 171 reduced holdings. 64 funds opened positions while 178 raised stakes. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported. Reilly Fincl Ltd Co has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 95 shares. Farmers Merchants accumulated 79 shares. Brinker Capital accumulated 0.02% or 4,723 shares. Channing Mgmt Limited Liability holds 0.51% or 125,278 shares in its portfolio. Bailard invested 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Point72 Asia (Hong Kong) Ltd holds 30 shares. Ubs Asset Americas Inc owns 1.87 million shares. Peak6 Invs LP reported 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 5,120 are owned by Johnson Financial. Investec Asset Mgmt owns 0.35% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 703,203 shares. Nelson Van Denburg Campbell Wealth Mgmt Group Ltd Liability Corp accumulated 7 shares. 30,393 were reported by Suntrust Banks Incorporated. Thrivent Financial For Lutherans invested in 985,826 shares. Comerica has 3,245 shares. Fort Washington Investment Advisors Oh has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts